SG11201810371XA - ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - Google Patents
ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOFInfo
- Publication number
- SG11201810371XA SG11201810371XA SG11201810371XA SG11201810371XA SG11201810371XA SG 11201810371X A SG11201810371X A SG 11201810371XA SG 11201810371X A SG11201810371X A SG 11201810371XA SG 11201810371X A SG11201810371X A SG 11201810371XA SG 11201810371X A SG11201810371X A SG 11201810371XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- indianapolis
- rule
- n3pglu
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 011111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/005282 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: Declarations under Rule 4.17: C07K 16/18 (2006.01) A61P 25/28 (2006.01) A61K 39/395 (2006.01) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) (21) International Application Number: — as to the applicant's entitlement to claim the priority of the PCT/US2017/038999 earlier application (Rule 4.17(iii)) (22) International Filing Date: Published: 23 June 2017 (23.06.2017) — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/357,579 01 July 2016 (01.07.2016) US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: DEMATTOS, Ronald Bradley; c/o ELI LIL- LY AND COMPANY, P.O. Box 6288, Indianapolis, Indi- ana 46206-6288 (US). IRIZARRY, Michael Carl; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, In- diana 46206-6288 (US). — = Agent: JIVRAJ, Sanjay M. et al.; ELI LILLY AND COM- (74) _ PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 = (US). Designated States (unless otherwise indicated, for every = (81) kind of national protection available): AE, AG, AL, AM, = _ AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = — 1-1 ei GC N kr) 0 C:::: ) (54) Title: ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF --.... ,-1 (57) : The invention is directed to a short term induction treatment with anti-N3pGlu AO antibodies of a disease characterized 0 by deposition of AO in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). \" In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu AO antibody for a period 0 of 6 months or less.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357579P | 2016-07-01 | 2016-07-01 | |
| PCT/US2017/038999 WO2018005282A1 (en) | 2016-07-01 | 2017-06-23 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810371XA true SG11201810371XA (en) | 2018-12-28 |
Family
ID=59295341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810371XA SG11201810371XA (en) | 2016-07-01 | 2017-06-23 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11312763B2 (en) |
| EP (2) | EP3478712B1 (en) |
| JP (4) | JP7165588B2 (en) |
| KR (3) | KR20230021773A (en) |
| CN (3) | CN114887054A (en) |
| AU (1) | AU2017291414B2 (en) |
| BR (1) | BR112018073843A2 (en) |
| CA (1) | CA3029550C (en) |
| DK (1) | DK3478712T3 (en) |
| EA (1) | EA201892690A1 (en) |
| ES (1) | ES2958508T3 (en) |
| FI (1) | FI3478712T3 (en) |
| HR (1) | HRP20230861T1 (en) |
| HU (1) | HUE062980T2 (en) |
| IL (1) | IL263788A (en) |
| LT (1) | LT3478712T (en) |
| MA (1) | MA45543B1 (en) |
| MD (1) | MD3478712T2 (en) |
| MX (2) | MX2018016066A (en) |
| PL (1) | PL3478712T3 (en) |
| PT (1) | PT3478712T (en) |
| RS (1) | RS64386B1 (en) |
| SG (1) | SG11201810371XA (en) |
| SI (1) | SI3478712T1 (en) |
| TW (2) | TWI798751B (en) |
| UA (1) | UA127101C2 (en) |
| WO (1) | WO2018005282A1 (en) |
| ZA (1) | ZA201807633B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI798751B (en) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| JOP20190247A1 (en) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| EP3521308B1 (en) * | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
| WO2019169448A1 (en) * | 2018-03-09 | 2019-09-12 | St Vincent's Institute Of Medical Research | Multi-specific antibodies |
| AU2019309938A1 (en) * | 2018-07-24 | 2021-03-11 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| CN111184725B (en) * | 2020-02-27 | 2020-12-01 | 慈溪市人民医院医疗健康集团(慈溪市人民医院) | Medicinal preparation for preventing and treating cerebral infarction and preparation method thereof |
| US20240010713A1 (en) * | 2021-01-11 | 2024-01-11 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| JP2023067832A (en) * | 2021-10-29 | 2023-05-16 | イーライ リリー アンド カンパニー | Compounds and methods targeting interleukin-34 |
| WO2023076970A1 (en) * | 2021-10-29 | 2023-05-04 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| WO2023146818A2 (en) * | 2022-01-26 | 2023-08-03 | T3D Therapeutics, Inc. | Methods of treating amyloid related brain disorders using novel compounds and antibodies |
| WO2023150483A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1397539A (en) * | 1920-01-14 | 1921-11-22 | Odell Risdon Moore | Egg-carton |
| IL151378A0 (en) | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| WO2004013172A2 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| JP5042828B2 (en) | 2004-07-30 | 2012-10-03 | ライナット ニューロサイエンス コーポレイション | Antibodies directed against amyloid-beta peptide and methods using the antibodies |
| EP2377886A1 (en) | 2005-12-12 | 2011-10-19 | F. Hoffmann-La Roche AG | Antibody glycosylation in the variable region |
| KR101413615B1 (en) | 2006-03-23 | 2014-07-18 | 바이오악틱 뉴로사이언스 에이비 | Improved antibody selective for human protofibrils and the use thereof |
| WO2009017467A1 (en) * | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| AU2007275467B2 (en) | 2006-07-14 | 2013-12-05 | Ac Immune S.A. | Humanized antibody against amyloid beta |
| AU2008206555B2 (en) | 2007-01-18 | 2013-07-04 | Eli Lilly And Company | Pegylated Abeta Fab |
| WO2009149487A2 (en) | 2008-06-12 | 2009-12-17 | Affiris Ag | Compounds for treating symptoms associated with parkinson's disease |
| CA2730073A1 (en) | 2008-07-09 | 2010-01-14 | University Of Zurich | Method of promoting neurogenesis |
| BRPI0916366B1 (en) | 2008-07-21 | 2021-08-10 | Probiodrug Ag | ANTIBODY THAT LINKS TO ABETA PEPTIDE VARIANTS, THEIR COMPOSITION, USE, DIAGNOSTIC KIT, AND HYBRIDOMA CELL LINEAGE |
| CN101397539B (en) * | 2008-10-14 | 2011-10-05 | 中国人民解放军第三军医大学 | Force application apparatus simulating human physiological stress of tissue bionic culture for tissue engineering |
| UA108363C2 (en) | 2009-10-08 | 2015-04-27 | IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS | |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| WO2012021475A2 (en) | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| HUE037524T2 (en) * | 2010-08-12 | 2018-09-28 | Lilly Co Eli | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| EA201591019A1 (en) | 2012-12-07 | 2015-11-30 | Байоджен Интернэшнл Нейросайенз Гмбх | A METHOD FOR REDUCING THE NUMBER OF AMYLOID PLATES IN THE BRAIN WITH ANTI-Aβ ANTITAL |
| TWI593692B (en) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | Tetrahydropyrrolothiazine compounds |
| MX2016010237A (en) | 2014-02-08 | 2017-04-27 | Genentech Inc | Methods of treating alzheimer's disease. |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| WO2015191825A1 (en) * | 2014-06-13 | 2015-12-17 | Biogen Ma Inc. | Methods for the detection and measurement of amyloid beta in biological samples |
| JP6201928B2 (en) * | 2014-08-04 | 2017-09-27 | トヨタ自動車株式会社 | Vehicle control device |
| TWI570127B (en) | 2014-09-15 | 2017-02-11 | 美國禮來大藥廠 | Crystalline n-[3- [(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7- tetrahydropyrrolo [3,4-d] [ 1 ,3]thiazin-7a-yl] -4-fluoro-phenyl] -5 -methoxy- pyrazine-2-carboxamide, and use and pharmaceutical composition thereof |
| TWI599358B (en) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | Combination therapy |
| WO2016053767A1 (en) | 2014-09-30 | 2016-04-07 | Merck Sharp & Dohme Corp. | Novel crystalline forms of a bace inhibitor, compositions, and their use |
| MA41115A (en) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | ALZHEIMER'S DISEASE TREATMENT PROCESS |
| JOP20170004B1 (en) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | ANTl-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| TWI798751B (en) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
-
2017
- 2017-06-16 TW TW110125726A patent/TWI798751B/en active
- 2017-06-16 TW TW106120115A patent/TWI735600B/en active
- 2017-06-23 AU AU2017291414A patent/AU2017291414B2/en active Active
- 2017-06-23 EP EP17736841.2A patent/EP3478712B1/en active Active
- 2017-06-23 WO PCT/US2017/038999 patent/WO2018005282A1/en unknown
- 2017-06-23 FI FIEP17736841.2T patent/FI3478712T3/en active
- 2017-06-23 MX MX2018016066A patent/MX2018016066A/en unknown
- 2017-06-23 BR BR112018073843-3A patent/BR112018073843A2/en unknown
- 2017-06-23 EA EA201892690A patent/EA201892690A1/en unknown
- 2017-06-23 RS RS20230595A patent/RS64386B1/en unknown
- 2017-06-23 LT LTEPPCT/US2017/038999T patent/LT3478712T/en unknown
- 2017-06-23 SG SG11201810371XA patent/SG11201810371XA/en unknown
- 2017-06-23 HU HUE17736841A patent/HUE062980T2/en unknown
- 2017-06-23 EP EP23176986.0A patent/EP4272828A3/en active Pending
- 2017-06-23 DK DK17736841.2T patent/DK3478712T3/en active
- 2017-06-23 PT PT177368412T patent/PT3478712T/en unknown
- 2017-06-23 US US16/310,629 patent/US11312763B2/en active Active
- 2017-06-23 CN CN202210683585.6A patent/CN114887054A/en active Pending
- 2017-06-23 CA CA3029550A patent/CA3029550C/en active Active
- 2017-06-23 KR KR1020237004025A patent/KR20230021773A/en not_active Application Discontinuation
- 2017-06-23 CN CN202210683554.0A patent/CN114917338A/en active Pending
- 2017-06-23 ES ES17736841T patent/ES2958508T3/en active Active
- 2017-06-23 KR KR1020217005333A patent/KR20210024213A/en not_active IP Right Cessation
- 2017-06-23 MA MA45543A patent/MA45543B1/en unknown
- 2017-06-23 JP JP2018567740A patent/JP7165588B2/en active Active
- 2017-06-23 KR KR1020187037757A patent/KR102221402B1/en active IP Right Grant
- 2017-06-23 CN CN201780040635.6A patent/CN109415433A/en active Pending
- 2017-06-23 HR HRP20230861TT patent/HRP20230861T1/en unknown
- 2017-06-23 UA UAA201811726A patent/UA127101C2/en unknown
- 2017-06-23 MD MDE20190551T patent/MD3478712T2/en unknown
- 2017-06-23 PL PL17736841.2T patent/PL3478712T3/en unknown
- 2017-06-23 SI SI201731389T patent/SI3478712T1/en unknown
-
2018
- 2018-11-13 ZA ZA2018/07633A patent/ZA201807633B/en unknown
- 2018-12-18 MX MX2023001299A patent/MX2023001299A/en unknown
- 2018-12-18 IL IL263788A patent/IL263788A/en unknown
-
2020
- 2020-12-03 JP JP2020201051A patent/JP2021059547A/en active Pending
- 2020-12-03 JP JP2020201050A patent/JP7241058B2/en active Active
-
2022
- 2022-04-01 US US17/711,099 patent/US20220235122A1/en active Pending
-
2023
- 2023-06-06 JP JP2023093033A patent/JP2023123503A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones |